期刊
INFLUENZA AND OTHER RESPIRATORY VIRUSES
卷 9, 期 4, 页码 169-178出版社
WILEY
DOI: 10.1111/irv.12313
关键词
respiratory syncytial virus; respiratory syncytial virus antivirals; respiratory syncytial virus prophylactic antibodies; respiratory syncytial virus vaccines
资金
- Public Health Agency [RRG/3244/05] Funding Source: researchfish
As the most important viral cause of severe respiratory disease in infants and increasing recognition as important in the elderly and immunocompromised, respiratory syncytial virus (RSV) is responsible for a massive health burden worldwide. Prophylactic antibodies were successfully developed against RSV. However, their use is restricted to a small group of infants considered at high risk of severe RSV disease. There is still no specific therapeutics or vaccines to combat RSV. As such, it remains a major unmet medical need for most individuals. The World Health Organisations International Clinical Trials Registry Platform (WHO ICTRP) and PubMed were used to identify and review all RSV vaccine, prophylactic and therapeutic candidates currently in clinical trials. This review presents an expert commentary on all RSV-specific prophylactic and therapeutic candidates that have entered clinical trials since 2008.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据